Search research articles
Contact Us
Filters
Showing results (71-80 of 157) with videos related to
Page
of 16
Sort By:
Journal of Hepatology
|
November 5, 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, et al.
Gastroenterology
|
July 15, 2015
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
Eric Lawitz, Mihály Makara, Ulus Salih Akarca, et al.
Clinical Pharmacokinetics
|
March 27, 2025
Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment
Maulik Patel, Jalaja Potluri, Thomas Marbury, et al.
Journal of Hepatology
|
December 8, 2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
David Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Journal of Hepatology
|
November 6, 2021
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Vlad Ratziu, Mary E Rinella, Brent A Neuschwander-Tetri, et al.
Viruses
|
October 28, 2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
Steven Flamm, Eric Lawitz, Brian Borg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 1, 2019
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials
Ashley Brown, Tania M Welzel, Brian Conway, et al.
Antiviral Therapy
|
February 8, 2014
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor
David Nelson, Eric M Yoshida, Matthew S Paulson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
Maria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Alimentary Pharmacology & Therapeutics
|
November 27, 2025
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis
Juan Frias, Robert Schmouder, Eric Lawitz, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 157) with videos related to
Sort By:
Page
of 16
Journal of Hepatology
|
November 5, 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, et al.
Gastroenterology
|
July 15, 2015
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
Eric Lawitz, Mihály Makara, Ulus Salih Akarca, et al.
Clinical Pharmacokinetics
|
March 27, 2025
Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment
Maulik Patel, Jalaja Potluri, Thomas Marbury, et al.
Journal of Hepatology
|
December 8, 2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
David Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Journal of Hepatology
|
November 6, 2021
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Vlad Ratziu, Mary E Rinella, Brent A Neuschwander-Tetri, et al.
Viruses
|
October 28, 2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
Steven Flamm, Eric Lawitz, Brian Borg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 1, 2019
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials
Ashley Brown, Tania M Welzel, Brian Conway, et al.
Antiviral Therapy
|
February 8, 2014
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor
David Nelson, Eric M Yoshida, Matthew S Paulson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
Maria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Alimentary Pharmacology & Therapeutics
|
November 27, 2025
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis
Juan Frias, Robert Schmouder, Eric Lawitz, et al.
Page
of 16